Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.482 DKK -0.13% Market Closed
Market Cap: 636.8m DKK
Have any thoughts about
Bioporto A/S?
Write Note

Bioporto A/S
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bioporto A/S
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Bioporto A/S
CSE:BIOPOR
Gross Profit
kr24.1m
CAGR 3-Years
19%
CAGR 5-Years
6%
CAGR 10-Years
8%
Genmab A/S
CSE:GMAB
Gross Profit
kr18.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Gross Profit
kr55.4m
CAGR 3-Years
-23%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Gross Profit
€277.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Gross Profit
kr3.5B
CAGR 3-Years
91%
CAGR 5-Years
62%
CAGR 10-Years
19%
Saniona AB
STO:SANION
Gross Profit
-kr22.9m
CAGR 3-Years
53%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Bioporto A/S
Glance View

Market Cap
636.8m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.301 DKK
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Bioporto A/S's Gross Profit?
Gross Profit
24.1m DKK

Based on the financial report for Jun 30, 2024, Bioporto A/S's Gross Profit amounts to 24.1m DKK.

What is Bioporto A/S's Gross Profit growth rate?
Gross Profit CAGR 10Y
8%

Over the last year, the Gross Profit growth was 25%. The average annual Gross Profit growth rates for Bioporto A/S have been 19% over the past three years , 6% over the past five years , and 8% over the past ten years .

Back to Top